These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30336197)

  • 1. Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
    Xiao YS; Zeng D; Liang YK; Wu Y; Li MF; Qi YZ; Wei XL; Huang WH; Chen M; Zhang GJ
    Cancer Lett; 2019 Jan; 440-441():156-167. PubMed ID: 30336197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
    Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
    Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
    Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
    Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
    Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
    Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
    Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
    Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.
    Xie X; Kaoud TS; Edupuganti R; Zhang T; Kogawa T; Zhao Y; Chauhan GB; Giannoukos DN; Qi Y; Tripathy D; Wang J; Gray NS; Dalby KN; Bartholomeusz C; Ueno NT
    Oncogene; 2017 May; 36(18):2599-2608. PubMed ID: 27941886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.
    Miao K; Lei JH; Valecha MV; Zhang A; Xu J; Wang L; Lyu X; Chen S; Miao Z; Zhang X; Su SM; Shao F; Rajendran BK; Bao J; Zeng J; Sun H; Chen P; Tan K; Chen Q; Wong KH; Xu X; Deng CX
    Nat Commun; 2020 Jun; 11(1):3256. PubMed ID: 32591500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells.
    Piwarski SA; Thompson C; Chaudhry AR; Denvir J; Primerano DA; Fan J; Salisbury TB
    Biochem Pharmacol; 2020 Apr; 174():113845. PubMed ID: 32032581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).
    Lehuédé C; Li X; Dauvillier S; Vaysse C; Franchet C; Clement E; Esteve D; Longué M; Chaltiel L; Le Gonidec S; Lazar I; Geneste A; Dumontet C; Valet P; Nieto L; Fallone F; Muller C
    Breast Cancer Res; 2019 Jan; 21(1):7. PubMed ID: 30654824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
    Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
    Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination.
    Li J; Gao R; Zhang J
    Clin Breast Cancer; 2023 Feb; 23(2):162-175. PubMed ID: 36528490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression.
    Siddharth S; Parida S; Muniraj N; Hercules S; Lim D; Nagalingam A; Wang C; Gyorffy B; Daniel JM; Sharma D
    Elife; 2021 Dec; 10():. PubMed ID: 34889737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
    Zhang M; Meng M; Liu Y; Qi J; Zhao Z; Qiao Y; Hu Y; Lu W; Zhou Z; Xu P; Zhou Q
    Breast Cancer Res; 2021 Dec; 23(1):116. PubMed ID: 34922602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231.
    Yang M; Li Y; Ruan Y; Lu Y; Lin D; Xie Y; Dong B; Dang Q; Quan C
    Mol Cell Biochem; 2018 Jun; 443(1-2):169-180. PubMed ID: 29159771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
    Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
    Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.